TEVA grants 37,982 RSUs to officer Jover Placid

Jover Placid reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Jover Placid reported acquisition or exercise transactions in this Form 4 filing.

TEVA PHARMACEUTICAL INDUSTRIES LTD reported that officer Jover Placid received a grant of 37,982 restricted share units on March 4, 2026. Each restricted share unit represents a contingent right to receive one ordinary share, or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share.

The award vests in four annual installments, with 9,495 units vesting on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 9,497 units vesting on March 4, 2030. The ordinary shares may be represented by American Depositary Shares, each currently corresponding to one ordinary share.

Insider Trade Summary

Grant/Award: 37,982 shares

Grant/Award 1 txn

Insider Jover Placid

Role See "Remarks"

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	37,982	$0.00	$0.00

Holdings After Transaction: Restricted Share Units — 37,982 contracts (Direct)

Footnotes (3)

1. F1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
2. F2. Restricted share units were granted on March 4, 2026, with 9,495 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 9,497 vesting on March 4, 2030.
3. F3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TEVA (TEVA) report for Jover Placid?

TEVA reported that officer Jover Placid received a grant of 37,982 restricted share units on March 4, 2026. This is an equity-based compensation award, not an open-market stock purchase or sale, and it increases his potential future ownership stake subject to vesting.

How do the 37,982 restricted share units at TEVA vest over time?

The 37,982 restricted share units vest in four annual tranches. 9,495 units vest on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 9,497 units vest on March 4, 2030, subject to the award’s terms and conditions.

What does each TEVA restricted share unit granted to Jover Placid represent?

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share of TEVA or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share, providing flexibility in how the award is ultimately settled.

Are TEVA’s ordinary shares from these RSUs linked to American Depositary Shares (ADS)?

Yes. The filing states TEVA’s ordinary shares may be represented by American Depositary Shares, with each ADS currently representing one ordinary share. This means settled RSUs could correspond to ADSs for investors who hold TEVA through depositary receipts.

Did Jover Placid buy or sell TEVA shares in the market in this Form 4?

No market purchase or sale is reported. The Form 4 shows an acquisition coded as a grant or award of 37,982 restricted share units, reflecting stock-based compensation rather than an open-market trading transaction by Jover Placid.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jover Placid

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See "Remarks"

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	03/04/2026		A		37,982		(2)	(2)	Ordinary Shares(3)	37,982	$0	37,982	D

Explanation of Responses:

1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

2. Restricted share units were granted on March 4, 2026, with 9,495 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 9,497 vesting on March 4, 2030.

3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Remarks:

Executive Vice President, Chief Human Resources Officer

	/s/ Dov Bergwerk as attorney-in-fact for Placid Jover	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.